GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Anthropic IPO Marketing Expected to Start in Mid-October 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
 and NASH to be Rescheduled - EconoTimes)
Add as a preferred source on Google
LIVONIA, Mich., Feb. 27, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that due to a family emergency of one of the a panel members, it will need to reschedule the expert panel call discussing pediatric nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that was scheduled for Wednesday, February 28. A new date and time for the expert panel call will be announced as soon as possible.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
